Home › NDC Lookup › RxCUI directory › RxCUI 2632552

Dabrafenib 10 MG Tablet for Oral Suspension — RxCUI 2632552

RxNorm drug concept · Semantic clinical drug
RxCUI 2632552 Semantic clinical drug · SCD ● Current RxNorm concept 3 FDA products 3 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2632552
Official nameDabrafenib 10 MG Tablet for Oral Suspension
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asdabrafenib 10 MG (as dabrafenib mesylate 11.85 MG) Tablet for Oral Suspension
FDA products mapped3
Package NDCs mapped3
Reported Medicaid activity (SDUD)2,673 prescriptions · 24 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Dabrafenib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Dabrafenib only works on tumors that carry a specific BRAF gene mutation — usually called V600E or V600K. Without that mutation, the drug won't help and could actually encourage tu...
  • Why do I need a genetic test before starting dabrafenib?
  • Yes, and this is one of the most important practical points. You need to take it on an empty stomach — at least 1 hour before eating or 2 hours after. A high-fat meal can cut by ro...
  • Does it matter when I take dabrafenib relative to meals?
📖 Read our full Dabrafenib guide →

🕸️ Concept Web — How Dabrafenib 10 MG Tablet for Oral Suspension Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Dabrafenib 10 MG Tablet for Oral Suspension RxCUI 2632552

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Dabrafenib 1424911
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Tafinlar 1425223
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Dabrafenib Tablet for Oral Suspension 2632551
    • Dabrafenib Oral Liquid Product 2632550
    • Dabrafenib Oral Product 1424913
    • Dabrafenib Tablet for Oral Suspension [Tafinlar] 2632555
    • Tafinlar Oral Liquid Product 2632554
    • Tafinlar Oral Product 1425226
    • Tablet for Oral Suspension 1861409
    • Oral Liquid Product 1151137
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Dabrafenib 10 MG SCDC · 2632549
  • Dabrafenib Tablet for Oral Suspension SCDF · 2632551
  • Dabrafenib Oral Liquid Product SCDG · 2632550
  • Dabrafenib Oral Product SCDG · 1424913

Brand-Name Concepts

  • Dabrafenib 10 MG Tablet for Oral Suspension [Tafinlar] SBD · 2632556
  • Dabrafenib 10 MG [Tafinlar] SBDC · 2632553
  • Dabrafenib Tablet for Oral Suspension [Tafinlar] SBDF · 2632555
  • Tafinlar Oral Liquid Product SBDG · 2632554
  • Tafinlar Oral Product SBDG · 1425226
  • Tafinlar BN · 1425223

📦 FDA Products & Package NDCs

3 products · 3 package NDCs
3 package NDCs map to RxCUI 2632552 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00078-0681-66 120 CAPSULE in 1 BOTTLE (0078-0681-66) Tafinlar Novartis Pharmaceuticals Corporation 2016-04-01
00078-0682-66 120 CAPSULE in 1 BOTTLE (0078-0682-66) Tafinlar Novartis Pharmaceuticals Corporation 2016-04-12
00078-1154-21 210 TABLET, FOR SUSPENSION in 1 BOTTLE (0078-1154-21) Tafinlar Novartis Pharmaceuticals Corporation 2023-03-16
Observed labelers: Novartis Pharmaceuticals Corporation (3) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.